Sam Chang, MD
A graduate of Princeton University and Vanderbilt University Medical School, Sam S. Chang, MD, completed his uro-oncology fellowship as Chief Fellow at Memorial Sloan-Kettering Cancer Center and is currently the holder of the Patricia and Rodes Hart Chair in Urologic Surgery and Professor of Urologic Surgery at Vanderbilt University Medical Center.
As Chairman of the SUO Panel on Hormone Refractory Prostate Cancer, the Chair of the AUA Guidelines on Noninvasive Bladder Cancer, former chair of the AUA Prostate Cancer Core Curriculum Committee, and Facilitator of the AUA Guidelines on Renal Cancer Followup, Dr. Chang has participated in framing diagnosis, treatment, and followup for a variety of urologic malignancies. As an AUA-EAU Academic Exchange Fellow, he further promoted critical evidentiary analysis and educational reforms.
As past Chair of the AJCC GU Staging Task Force responsible for staging criteria for all urologic malignancies, he oversaw the 2010 AJCC Staging update. Additional leadership roles have included roles on the SUO Executive Board, ABU/AUA Examination Committee, BCAN Advisory Board, Commission on Cancer, NCCN Testis and Kidney Cancer Guidelines, the AUA Education and Public Promotion Committees, AUA representative to the AJCC, and AUA Foundation Prostate Advisory Board.
Dr. Chang has authored more than 200 original publications. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award, a CaPCURE Young Investigator Award, the Journal of Urology’s Best Reviewer Award and the AUA Gold Cystoscope Award.
Financial relationships
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:ProkariumDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (Oncology)Ineligible company:mIRDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:virtuoso surgicalDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:GLGDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Scientific Study or Trial (General Urology)Ineligible company:NIHDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:JanssenDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Health Publishing (General Urology)Ineligible company:Uro TodayDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:urogenDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:pfizerDate added:Date updated:12/22/2021
-
Attribution:SelfType of financial relationship:Consultant or Advisor (General Urology)Ineligible company:BMSDate added:Date updated:12/22/2021